Effect of Early Administration of TXA in Adult Hip Fractures
Does Early Administration of Tranexamic Acid Decrease Perioperative Blood Loss in Addition to Intraoperative Tranexamic Acid for Hip Fracture Patients?
Ascension Health
170 participants
Sep 1, 2021
INTERVENTIONAL
Conditions
Summary
This is a prospective clinical study designed to assess blood loss in intracapsular and extracapsular hip fractures undergoing operative fixation at a Level II trauma center. It is well established in the orthopedic literature that tranexamic acid (TXA) decreases blood loss and need for postoperative blood transfusion in hip fracture patients as well as total joint arthroplasty patients. A typical dosing pattern, and the dosing pattern employed at our institution, is 1 gram IV infused prior to incision followed by 1 gram IV infused at the time of wound closure.
Eligibility
Inclusion Criteria1
- \. All adult (18 years old or older) hip fracture patients presenting with an acute hip fracture and undergoing operative fixation
Exclusion Criteria9
- Polytrauma patients
- Previous operation on the ipsilateral hip
- Patients with coagulopathies (Factor V Leiden, Sickle Cell Anemia, Etc.)
- Patients with \< 6-month history of thromboembolic event (DVT/PE), Stroke, Cardiac Stents, or Myocardial Infarction (MI)
- History of seizure disorder
- Patients on birth control
- Pregnant Women
- Prisoners
- Active thromboembolic disease (DVT/PE, MI, Stroke)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
TXA to be given at time of diagnosis in the emergency department (ED) in treatment group and at time of operation for both groups
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05047133